Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Sachi Sakaguchi"'
Publikováno v:
Case Reports in Hematology, Vol 2016 (2016)
We describe the case of a 13-year-old boy who presented with persistent thrombocytopenia during maintenance chemotherapy with mercaptopurine and methotrexate for T cell lymphoblastic lymphoma. He was diagnosed with immune thrombocytopenia (ITP) after
Externí odkaz:
https://doaj.org/article/219d4030234b45df8204b063564c37a0
Autor:
Masakazu Toi, Chiun‐Sheng Huang, Young‐Hyuck Im, Joohyuk Sohn, Wei Zhang, Sachi Sakaguchi, Nadine Haddad, Gertjan van Hal, George W. Sledge
Publikováno v:
Cancer Science. 114:221-226
MONARCH 2 is a global, randomized, double-blind, phase 3 study of abemaciclib/placebo + fulvestrant in patients with hormone receptor positive, human epidermal growth factor receptor 2-negative advanced breast cancer. The East Asian population compri
Autor:
Jan-Stefan van der Walt, Joji Mori, Takahiro Nakayama, Kenichi Inoue, Yoshinori Ito, George W. Sledge, Yasuo Miyoshi, Tsutomu Kawaguchi, Masato Takahashi, Yoshinori Tanizawa, Masakazu Toi, Antonio Llombart-Cussac, Norikazu Masuda, Hiroji Iwata, Hirofumi Mukai, Sachi Sakaguchi
Publikováno v:
Breast Cancer (Tokyo, Japan)
Background This was a Japanese subpopulation analysis of MONARCH 2, a double-blind, randomized, placebo-controlled, phase 3 study of abemaciclib plus fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-neg
Autor:
Masafumi Ikeda, Richard S. Finn, Ryan C. Widau, Paolo Abada, Kun Liang, Sachi Sakaguchi, Peter R. Galle, Chunxiao Wang, Andrew X. Zhu, Tatsuya Yamashita, Masatoshi Kudo
Publikováno v:
Hepatology Research. 51:715-721
Aim The REACH and REACH-2 trials investigated ramucirumab versus placebo in patients with advanced hepatocellular carcinoma (HCC). Ascites is common in HCC and is associated with poorer outcomes. This exploratory, pooled meta-analysis of patients wit
Autor:
Masakazu Toi, In Hae Park, Seock-Ah Im, Sachi Sakaguchi, Molly C. Hardebeck, P. Kellie Turner, Norikazu Masuda, Sotaro Enatsu, Matthew P. Goetz, Hiroji Iwata, George W. Sledge, Valerie Andre, Shin-Cheh Chen, Kenichi Inoue, Joohyuk Sohn
Publikováno v:
Cancer Science
This post hoc analysis of MONARCH 2 and MONARCH 3 assesses the efficacy, safety, and pharmacokinetics (PK) of abemaciclib in combination with endocrine therapy (ET) in East Asian patients with hormone receptor positive (HR+), human epidermal growth f
Publikováno v:
Drugs-Real World Outcomes
Background Evidence about the relationship between albumin-bilirubin (ALBI) grade and sequential systemic therapy for advanced hepatocellular carcinoma in real-world Japanese clinical practice is limited. Objective The objective of this study was to
Autor:
Makoto Kodaira, Toshihiro Kudo, Koichi Inoue, Kenji Nakano, Sachi Sakaguchi, Yuichi Ando, Joji Mori, Gerard J. Oakley, Taroh Satoh, Shunji Takahashi, Kenji Tamura, Tomoya Shimokata, Kan Yonemori
Publikováno v:
Cancer Science
Olaratumab, a monoclonal antibody targeting human platelet‐derived growth factor receptor α, plus doxorubicin significantly improved overall survival in patients with advanced soft‐tissue sarcoma (STS) in a prior phase 1b/2 randomized trial. Sub
Autor:
Masashi Takahashi, Shiho Mori, Keisuke Tomii, Junji Tsurutani, Satoshi Noma, Hiroya Asou, Yoshio Taguchi, Sachi Sakaguchi, Yucherng Chen
Publikováno v:
Breast Cancer (Tokyo, Japan)
Background This study evaluated characteristics of patients treated with abemaciclib and diagnosed with interstitial lung disease (ILD), using 12-month post-marketing data from the real-world setting in Japan. Methods Spontaneous reports of adverse e
Autor:
Naoko Maeda, Sachi Sakaguchi, Masatoshi Takagi, Kentaro Nakashima, Hirohide Kawasaki, Yuji Miyajima, Hitoshi Sano, Souichi Adachi, Katsuyoshi Koh, Takashi Taga, Akihiro Watanabe, Yasushi Ishida, Toshihiko Imamura, Daiichiro Hasegawa, Tomohiko Taki, Atsushi Manabe
Publikováno v:
International Journal of Hematology. 108:438-442
Myeloid sarcoma (MS) is a rare neoplastic condition that is often described in association with acute myeloid leukemia (AML). MS in childhood has received little attention, particularly in Japan. We carried out a nationwide retrospective analysis of
Autor:
Chihiro, Tamaki, Shinichi, Hayashi, Aki, Sato, Kaijiro, Maeda, Sachi, Sakaguchi, Sean, Buchanan, Sotaro, Enatsu
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 46(9)
Abemaciclib, a selective cyclin dependent kinases 4 and 6(CDK46)inhibitor, is under development for the treatment of hormone receptor(HR)-positive, HER2-negative breast cancer. CDK46 inhibitors attenuate Rb phosphorylation resulting in a G1 arrest an